ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Buy” from Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been assigned a consensus recommendation of “Buy” from the nineteen research firms that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $56.27.

Several equities research analysts have recently weighed in on ACAD shares. Citigroup started coverage on shares of ACADIA Pharmaceuticals in a report on Thursday, March 5th. They issued a “buy” rating and a $69.00 target price on the stock. Jefferies Financial Group started coverage on shares of ACADIA Pharmaceuticals in a report on Thursday, April 16th. They issued a “buy” rating and a $60.00 target price on the stock. Oppenheimer upped their target price on shares of ACADIA Pharmaceuticals from $48.00 to $53.00 and gave the stock a “market perform” rating in a report on Wednesday, May 27th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, Cowen reaffirmed a “buy” rating and issued a $66.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, March 5th.

Shares of ACAD stock traded down $0.87 during mid-day trading on Tuesday, reaching $48.02. The company’s stock had a trading volume of 1,048,775 shares, compared to its average volume of 1,349,451. ACADIA Pharmaceuticals has a 1-year low of $21.56 and a 1-year high of $53.70. The company has a market cap of $7.74 billion, a P/E ratio of -30.39 and a beta of 1.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.20 and a current ratio of 7.26. The firm’s 50-day moving average is $49.25 and its two-hundred day moving average is $44.46.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). ACADIA Pharmaceuticals had a negative net margin of 64.99% and a negative return on equity of 39.40%. The business had revenue of $90.07 million during the quarter, compared to analyst estimates of $90.76 million. During the same quarter in the prior year, the company posted ($0.59) EPS. The company’s quarterly revenue was up 43.1% compared to the same quarter last year. Sell-side analysts anticipate that ACADIA Pharmaceuticals will post -1.91 EPS for the current year.

In related news, EVP Austin D. Kim sold 1,072 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $49.22, for a total value of $52,763.84. Following the sale, the executive vice president now directly owns 3,513 shares in the company, valued at approximately $172,909.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 694,303 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was purchased at an average price of $31.51 per share, for a total transaction of $21,877,487.53. The disclosure for this purchase can be found here. Insiders sold a total of 313,877 shares of company stock worth $15,330,583 in the last ninety days. Insiders own 29.40% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Advisory Services Network LLC acquired a new stake in ACADIA Pharmaceuticals during the 4th quarter worth approximately $71,000. Dupont Capital Management Corp raised its holdings in ACADIA Pharmaceuticals by 20.7% during the 4th quarter. Dupont Capital Management Corp now owns 21,506 shares of the biopharmaceutical company’s stock worth $920,000 after buying an additional 3,685 shares during the period. Swiss National Bank raised its holdings in ACADIA Pharmaceuticals by 8.0% during the 1st quarter. Swiss National Bank now owns 224,004 shares of the biopharmaceutical company’s stock worth $9,464,000 after buying an additional 16,500 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its holdings in ACADIA Pharmaceuticals by 8.6% during the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 45,033 shares of the biopharmaceutical company’s stock worth $1,927,000 after buying an additional 3,574 shares during the period. Finally, Chartwell Investment Partners LLC grew its stake in shares of ACADIA Pharmaceuticals by 12.7% during the 1st quarter. Chartwell Investment Partners LLC now owns 28,446 shares of the biopharmaceutical company’s stock worth $1,202,000 after acquiring an additional 3,205 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Featured Story: Stocks at 52 Week High

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.